Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CROT_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CROT_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CROT_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CROT_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CROT_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CROT_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:000911718 | Prostate | Tumor | nucleotide metabolic process | 120/3246 | 489/18723 | 2.81e-05 | 3.41e-04 | 120 |
GO:000675317 | Prostate | Tumor | nucleoside phosphate metabolic process | 121/3246 | 497/18723 | 3.81e-05 | 4.41e-04 | 121 |
GO:000609126 | Skin | AK | generation of precursor metabolites and energy | 69/1910 | 490/18723 | 3.59e-03 | 2.16e-02 | 69 |
GO:0006091111 | Skin | cSCC | generation of precursor metabolites and energy | 224/4864 | 490/18723 | 1.13e-21 | 2.21e-19 | 224 |
GO:0019693112 | Skin | cSCC | ribose phosphate metabolic process | 146/4864 | 396/18723 | 9.28e-07 | 1.68e-05 | 146 |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
GO:0009259112 | Skin | cSCC | ribonucleotide metabolic process | 138/4864 | 385/18723 | 1.00e-05 | 1.30e-04 | 138 |
GO:0006163112 | Skin | cSCC | purine nucleotide metabolic process | 140/4864 | 396/18723 | 1.93e-05 | 2.27e-04 | 140 |
GO:0009150112 | Skin | cSCC | purine ribonucleotide metabolic process | 131/4864 | 368/18723 | 2.42e-05 | 2.76e-04 | 131 |
GO:00065758 | Skin | cSCC | cellular modified amino acid metabolic process | 73/4864 | 188/18723 | 7.11e-05 | 6.85e-04 | 73 |
GO:00066359 | Skin | cSCC | fatty acid beta-oxidation | 30/4864 | 74/18723 | 4.32e-03 | 2.27e-02 | 30 |
GO:00159362 | Skin | cSCC | coenzyme A metabolic process | 10/4864 | 18/18723 | 7.25e-03 | 3.44e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CROT | SNV | Missense_Mutation | | c.1454N>T | p.Ser485Leu | p.S485L | Q9UKG9 | protein_coding | deleterious(0.02) | benign(0.209) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CROT | SNV | Missense_Mutation | novel | c.245T>C | p.Ile82Thr | p.I82T | Q9UKG9 | protein_coding | deleterious(0.02) | possibly_damaging(0.677) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
CROT | SNV | Missense_Mutation | novel | c.874G>T | p.Ala292Ser | p.A292S | Q9UKG9 | protein_coding | tolerated(0.45) | benign(0.021) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CROT | SNV | Missense_Mutation | novel | c.1832C>T | p.Ser611Phe | p.S611F | Q9UKG9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CROT | SNV | Missense_Mutation | | c.217N>G | p.Gln73Glu | p.Q73E | Q9UKG9 | protein_coding | tolerated(1) | benign(0) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CROT | SNV | Missense_Mutation | novel | c.1283C>A | p.Ala428Asp | p.A428D | Q9UKG9 | protein_coding | deleterious(0.05) | possibly_damaging(0.588) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CROT | insertion | Frame_Shift_Ins | novel | c.1218_1219insTTGGAAGCACCTAGTA | p.Asp407LeufsTer11 | p.D407Lfs*11 | Q9UKG9 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CROT | insertion | In_Frame_Ins | novel | c.1353_1354insAAA | p.Ala451_Leu452insLys | p.A451_L452insK | Q9UKG9 | protein_coding | | | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
CROT | SNV | Missense_Mutation | rs751006687 | c.839G>A | p.Arg280Gln | p.R280Q | Q9UKG9 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CROT | SNV | Missense_Mutation | | c.1109T>C | p.Val370Ala | p.V370A | Q9UKG9 | protein_coding | tolerated(0.12) | benign(0.026) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |